Shares of Novavax, Inc. (NASDAQ:NVAX) ended Monday session in green amid volatile trading. The shares closed up +0.08 points or 4.44% at $1.88 with 9.15 million shares getting traded. Post opening the session at $1.76, the shares hit an intraday low of $1.76 and an intraday high of $1.92 and the price vacillated in this range throughout the day. The company has a market cap of $488.14 million and the numbers of outstanding shares have been calculated to be 271.19 million shares.
Novavax, Inc. (NVAX) announced it has rescheduled its 4th annual Investor and Analyst Meeting. The Company will host an Investor and Analyst update as part of its third quarter financial results conference call and webcast on Wednesday, November 9, 2016.
“We continue to analyze data from our Resolve clinical trial and map out the clinical path forward for our older adult RSV F Vaccine in the context of our other clinical programs,” said Stanley C. Erck, President and CEO. “We would like to finalize those plans and communicate them at the same time as our third quarter financial results call in early November. We look forward to providing the next steps in our RSV F Vaccine program, as well as an update on the path forward for additional programs in our pipeline and our financial and operating plan, which we will provide as a dedicated part of our November financial results.”
Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) ended Monday session in red amid volatile trading. The shares closed down -0.02 points or -0.04% at $45.04 with 6.86 million shares getting traded. Post opening the session at $45.76, the shares hit an intraday low of $44.89 and an intraday high of $45.85 and the price vacillated in this range throughout the day. The company has a market cap of $46.06 billion and the numbers of outstanding shares have been calculated to be 1.01 billion shares.
Teva Pharmaceutical Industries Ltd (TEVA) and Celltrion Healthcare announced that the companies have entered into an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada. CT-P10 is a proposed mAb biosimilar to Rituxan® (rituximab), which is used to treat patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Wegener’s Granulomatosis and Microscopic Polyangiitis (MPA). CT-P6 is a proposed mAb biosimilar to Herceptin® (trastuzumab), which is used for the treatment of HER2-overexpressing breast cancer and for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Combined annual net sales for Rituxan and Herceptin are approximately $6.5 billion in the U.S. and Canada.
“This commercial partnership with Celltrion enables Teva to expand into the upcoming wave of biosimilars and build on its strong position in the biosimilar space,” said Siggi Olafsson, President & CEO of Global Generic Medicines, Teva Pharmaceuticals. “The introduction of two additional mAb biosimilar candidates into our near-term pipeline bolsters our biosimilar portfolio and continues to leverage Teva’s unique cross-functional capabilities across both specialty and generic medicines. We look forward to our partnership with Celltrion with its expertise in mAb biosimilar development and manufacturing.”